Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Gliomas Clinical Trials

A listing of Gliomas medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (232) clinical trials

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

This study proposes to treat patients with the combination of erlotinib and temozolomide. Patients with relapsed, recurrent, refractory, or high risk malignancies whose tumors possess a non-synonymous mutation in EGFR, ERBB2, or JAK2V617F (JAK2) will be eligible for the study. Very few phase 2 clinical trials have been performed in ...

Phase

Phase I Study of APX005M in Pediatric CNS Tumors

This is a multicenter phase I trial of APX005M in patients with recurrent or refractory primary malignant central nervous system tumor, or newly diagnosed diffuse intrinsic pontine glioma. APX005M is a humanized IgG1 mAb that binds to CD40. APX005M binds to both human and cynomolgus monkey CD40 with high affinity, ...

Phase

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

PRIMARY OBJECTIVES: The primary objective of the study is to determine the 6-month progression free survival probability of patients with recurrent, bevacizumab nave glioblastoma multiforme treated with ERC1671 in combination with GM-CSF and cyclophosphamide plus bevacizumab as compared with patients receiving bevacizumab plus placebo controls. SECONDARY OBJECTIVES: To evaluate radiographic ...

Phase

IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Lower Grade Glioma

Lower grade gliomas (WHO grades II and III) are currently diffused disease with variability of tumor behaviors and of challenge to distinguish the margins in white-light microscope during the surgery. An integrated dual-modality approach combining preoperative positron emission tomography imaging with intraoperative optical guidance that target the same tumor biomarker ...

Phase N/A

The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma

This proposal is for a pilot study comparing volumes of 18F-DOPA-PET avidity with contrast enhancement and T2 FLAIR on MRI. Investigators then plan to compare patterns of failure with target volumes, pre-treatment MRI changes and pre-treatment 18F-DOPA-PET.

Phase

Disulfiram in Recurrent Glioblastoma

Disulfiram (Antabuse) is a well-tolerated, cheap, generic drug that has been in use since the 1950s to treat alcoholism. There is now an increasing amount of independent preclinical data to support disulfiram as an anticancer agent. The potency of disulfiram as an anticancer agent seems strengthened by copper. There is ...

Phase

Immunophenotyping From Blood of Patients With Malignant Gliomas

Patients with malignant glioma generally have a bad prognosis. To improve patients' situation new therapy options as well as new possibilities to determine prognosis and prediction more precisely are needed. One approach is the targeted activation of the immune system to recognize and eliminate tumor cells. Due to cerebral tumors ...

Phase N/A

Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors

PROTOCOL SUMMARY: Phase 1: Patients with non-hematologic malignancies that are recurrent, progressive, or refractory after standard up-front therapy receiving MEK162 will define the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and toxicity profile. Phase 2: Patients with recurrent or progressive tumors signaling through the ras/raf pathway after standard up-front therapy ...

Phase

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

177Lu-J591 is made up of two compounds called J591 and 177Lutetium (177Lu) that are joined together by a connecting molecule called "DOTA". J591 is a monoclonal antibody, or a type of protein. 177Lu is a radioactive molecule that is being tested for the possible treatment of cancer when joined to ...

Phase N/A

Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas

A pilot study to determine the safety and efficacy of chimeric antigen receptor T cell (autologous T cells transduced with a lentiviral vector expressing chimeric antigen receptor) personalized immunotherapy for patients with recurrent malignant gliomas based on the expression of tumor specific/associated antigens (EGFRVIII, IL13R2, Her-2, EphA2, CD133, GD2).

Phase